Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05551117 · OUTCOME

Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors · Source last updated 2026-02-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

What was measured

PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.

Groups in this outcome

Part 2

vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 24

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Part 2NANot reportedNANACannot be estimated due to insufficient number of events.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Cannot be estimated due to insufficient number of events.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    units
    Participants
description
PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.
dispersion Type
95% Confidence Interval
groups
  1. description
    vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks
    id
    OG000
    title
    Part 2
param Type
MEDIAN
reporting Status
POSTED
time Frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
title
Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice